Concepedia

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

Astrid Gruber, Magnus Björkholm, L Brinch, Stein A. Evensen, Bengt Gustavsson, Michael Hedenus, Gunnar Juliusson, Eva Löfvenberg, Ingerid Nesthus, Bengt Simonsson,

Leukemia Research · 2003 · 35 citations · 19 references

DOI

Concepts

References

19

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin et al. · Blood · 1997 · 868 citations

, , +8

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Catherine P. Leith, Kenneth J. Kopecky, I‐Ming Chen et al. · PubMed · 1999 · 579 citations · Full text

, , +13

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]

Lydia Campos, Denis Guyotat, E Archimbaud et al. · Blood · 1992 · 496 citations · Full text

, , +16

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

Alan F. List, Kenneth J. Kopecky, Cheryl L. Willman et al. · Blood · 2001 · 418 citations · Full text

, , +15

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

D Boesch, B Jachez, A Pourtier-Manzanedo et al. · PubMed · 1991 · 365 citations

, , +14